Ligand Pharmaceuticals Completes Global License and Supply Agreement With RODES, Inc.

Represented Ligand Pharmaceuticals, Inc. in a global license and supply agreement to RODES, Inc. for three Captisol-enabled™ (CE) programs. Under the terms of the agreements, for each program Ligand will be eligible to receive development and commercial milestone payments, revenue from the sales of Captisol®, and royalties of 8% to 11% on future net sales. RODES will be responsible for all costs related to the development and commercialization of the programs. Financial terms of the agreements were not disclosed. Read the press release.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.